Back to Browse Journals » Current Biomarker Findings » Volume 3

Immune biomarkers in irritable bowel syndrome: a review

Authors Gras-Miralles B, Kokkotou E

Received 24 October 2012

Accepted for publication 3 April 2013

Published 17 June 2013 Volume 2013:3 Pages 43—53


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Beatriz Gras-Miralles, Efi Kokkotou

Gastroenterology Department, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Abstract: Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder that affects about 9%–13% of the general population. IBS is one of the main reasons to consult a primary care physician, and nearly 30% of visits to a gastroenterologist are for IBS. The diagnosis of IBS relies on subjective, patient-reported symptoms, thus making urgent the need for IBS-specific biomarkers. The same biomarkers, or perhaps different ones, can also be used to monitor disease evolution and response to treatment. A significant number of studies have looked in the immune system for establishing IBS biomarkers, based on the concept that IBS might represent a condition of immune dysregulation somewhere in the spectrum between health and inflammatory bowel disease. Such biomarkers can be detected in blood, intestinal biopsies, or luminal contents. Overall, results are rarely consistent between studies; small sample size, patient and disease heterogeneity, presence of comorbidities, and variation in sampling might contribute to these discrepancies. So far, studies have failed to provide a diagnostic immune biomarker for IBS, but they have considerably advanced our understanding of the disease pathophysiology, including the role of the individual's genetic make-up, and of the host–microbial interactions. High throughput analysis of a large number of well characterized patients holds promise for developing appropriate biomarkers for IBS.

Keywords: neuroimmune interactions, mast cells, genetic polymorphisms, cytokines, toll-like receptors

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Novel tumor markers in the serum of testicular germ cell cancer patients: a review

Syring I, Müller SC, Ellinger J

Current Biomarker Findings 2014, 4:133-137

Published Date: 9 September 2014

Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years

MacConell L, Pencek R, Li Y, Maggs D, Porter L

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013, 6:31-41

Published Date: 21 January 2013

Biomarkers for early detection of acute kidney injury

Han WK

Current Biomarker Findings 2012, 2:77-85

Published Date: 1 October 2012

Molecular biomarkers of glioblastoma: current targets and clinical implications

Yoshimoto K, Mizoguchi M, Hata N, Amano T, Nakamizo A, Sasaki T

Current Biomarker Findings 2012, 2:63-76

Published Date: 4 September 2012

High sensitivity C-reactive protein: a biomarker for heart failure in children with univentricular heart disease

Lowenthal A, Natal-Hernandez L, Lowenthal S, Hills NK, Bernstein HS

Current Biomarker Findings 2012, 2:57-62

Published Date: 29 August 2012

Current and emerging biomarkers of hepatotoxicity

Yang X, Salminen WF, Schnackenberg LK

Current Biomarker Findings 2012, 2:43-55

Published Date: 24 August 2012